Synaptogenix Inc (SNPX)

[Cyosol]

There's actually nothing wrong with the placebo result itself. The problem was that placebo patients started out with a higher baseline, which makes it hard to compare against the bryo group that started out lower.

Severe patients did so bad that they were excluded from the current trial. I recommend reading the 2022 paper about the latest trial that I added to the ibox if you want to learn more about the details of it.

I don't think there's only a 1% chance of success and I doubt the NIH thinks that either, but even if you eliminate the 40mcg dose, Memantine, severe patients and adjust for baseline imbalance, the fact of the matter is that this is still a unique trial that will deliver unique results. The drug has never been tested for an extended period in humans like this and the risk of failure is very much real, contrary to what some may think about this being a sure thing.